INT236869

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.41
First Reported 2008
Last Reported 2008
Negated 0
Speculated 0
Reported most in Body
Documents 2
Total Number 2
Disease Relevance 2.68
Pain Relevance 0

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell differentiation (SRD5A1) small molecule metabolic process (SRD5A1) endoplasmic reticulum (SRD5A1)
cytoplasm (SRD5A1)
SRD5A1 (Homo sapiens)
Pain Link Frequency Relevance Heat
aspirin 3 45.40 Quite Low
cINOD 8 44.72 Quite Low
COX-2 inhibitor 1 39.20 Quite Low
Inflammation 4 5.00 Very Low Very Low Very Low
Bioavailability 2 5.00 Very Low Very Low Very Low
Central nervous system 1 5.00 Very Low Very Low Very Low
withdrawal 1 5.00 Very Low Very Low Very Low
Prostatitis 1 5.00 Very Low Very Low Very Low
Pain 1 5.00 Very Low Very Low Very Low
Kinase C 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Disease 23 100.00 Very High Very High Very High
Prostate Cancer 109 99.96 Very High Very High Very High
Benign Prostatic Hypertrophy 95 99.96 Very High Very High Very High
Diuresis 6 98.40 Very High Very High Very High
Overactive Bladder 41 96.16 Very High Very High Very High
Lower Urinary Tract Symptoms 28 79.96 Quite High
Hyperplasia 2 75.04 Quite High
Reprotox - General 1 7 59.00 Quite High
INFLAMMATION 8 44.16 Quite Low
Cancer 35 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Medical therapy is the most frequently used treatment for BPH. 5-alpha-reductase inhibitors impact the underlying disease and decrease PV; this results in improved symptoms, urinary flow and quality of life, and a reduced risk of AUR and BPH-related surgery.
Negative_regulation (decrease) of Negative_regulation (inhibitors) of 5-alpha-reductase associated with diuresis, benign prostatic hypertrophy, overactive bladder and disease
1) Confidence 0.41 Published 2008 Journal International Journal of Clinical Practice Section Abstract Doc Link PMC2440415 Disease Relevance 1.76 Pain Relevance 0
Because androgens are required for the development of prostate cancer[48] and men with lower 5-alpha-reductase activity have lower rate of prostate cancer, 5-alpha-reductase inhibitors have been considered for chemo-prevention of prostate cancer. 5-alpha-reductase inhibitors decrease the prostate levels of dihydrotestosterone and reduce the androgenic stimulation to the prostate, although the systemic androgenic effects are only mildly affected.
Negative_regulation (decrease) of Negative_regulation (inhibitors) of 5-alpha-reductase associated with prostate cancer
2) Confidence 0.41 Published 2008 Journal Indian Journal of Urology : IJU : Journal of the Urological Society of India Section Body Doc Link PMC2684344 Disease Relevance 0.93 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox